Covance CVD

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Covance Posts Light Results Relative to Peers, but Still on Track to Meet Full-Year Estimates

      Commentary

      Fri, 2 May 2014

      Covance reported first-quarter results that slightly ..... industrywide overcapacity and weak demand, but Covance has shown signs of improvement. The segment ..... however, it was boosted by 10.9% growth in Covance ’s large central lab business. The clinical

    2. Covance beats by $0.01, misses on revenue

      Headlines

      Thu, 1 May 2014

      Covance ( CVD ): Q1 EPS of $0.90 beats by $0.01 . Revenue of $620.1M (+6.9% Y/Y) misses by $11.91M . Press Release Post your comment!

    3. Charles River Posts Solid 4Q as Preclinical Services Finally Rebound

      Commentary

      Thu, 13 Feb 2014

      growth since 2008. Management stated it is stealing market share from competitors, which we believe is accurate given that Covance reported just 5% revenue growth for its early-stage business in the fourth quarter.

    4. Covance 4Q Results Meet Expectations, Early-Stage Business Shows Signs of Improvement

      Commentary

      Wed, 5 Feb 2014

      Covance reported solid fourth-quarter results that ..... growth in the clinical development business. Covance ’s book-to-bill ratio held steady at ..... growth is sustainable over the near term. Covance was able to leverage the strong growth into

    5. Late-Stage Businesses Drive Narrow Moats for CROs

      Headlines

      Fri, 29 Nov 2013

      the CROs we cover: Quintiles Q, Covance CVD , Parexel PRXL, ICON ICLR, Charles ..... enrollment and drug development. Covance CVD estimates that more than 50 ..... development CROs we cover--Quintiles, Covance , ICON, and Parexel--fueled by

    6. Early-Stage Business Appears to be Bottoming as Covance Reports Strong Earnings Growth

      Commentary

      Wed, 30 Oct 2013

      Covance reported third-quarter results that met ..... which bodes well for near-term growth. Covance ’s early-stage business appears to be ..... Charles River posted. On an adjusted basis, Covance ’s early-stage operating margin improved

    7. Charles River Posts Solid Earnings Growth Despite Ongoing Weakness in Early-Stage R&D Spending

      Commentary

      Wed, 30 Oct 2013

      growth this quarter, versus just 1% growth reported by Covance 's early-stage business. This outperformance has been ..... sales up 4.7% year to date, versus a 0.4% decline at Covance . Charles River's segment margin also increased slightly

    8. Pfizer Partnership Drives Margin Expansion in ICON's 3Q Results

      Commentary

      Thu, 24 Oct 2013

      operating margins, which would be in line with the margins currently posted by the late-stage businesses of competitors Covance and Quintiles. As a result of the strong quarter, management slightly raised its non-GAAP earnings per share guidance

    9. New Morningstar Analyst Report for Quintiles Transnational Holdings Inc

      Stock Reports

      Mon, 21 Oct 2013

      largely an unattractive business that lacks a competitive advantage.Quintiles' central lab business significantly trails Covance .Quintiles large size is likely to lead to slower growth than its peers.Quintiles leadership position allows it to benefit

    10. New Morningstar Analyst Report for Covance , Inc.

      Stock Reports

      Mon, 21 Oct 2013

      industrywide pricing for years to come. Covance invested $175 million to open its ..... because of industrywide oversupply. Covance has purchased Big Pharmaceutical ..... strategic partnerships, increasing Covance 's fixed costs and decreasing its

    « Prev12345Next »
    Content Partners